New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Neuro-oncology Chuntova, P., Chow, F., Watchmaker, P., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A., DePinho, R. A., Li, M. O., Wherry, E. J., Mitchell, D., Terabe, M., Wainwright, D. A., Berzofsky, J. A., Herold-Mende, C., Heath, J. R., Lim, M., Margolin, K. A., Chiocca, E. A., Kasahara, N., Ellingson, B. M., Brown, C., Chen, Y., Fecci, P., Reardon, D. A., Dunn, G. P., Liau, L. M., Costello, J. F., Wick, W., Cloughesy, T., Timmer, W. C., Wen, P. Y., Prins, R. M., Platten, M., Okada, H. 2020Abstract
Cancer immunotherapy has made remarkable advances with over fifty separate Food and Drug Administration (FDA) approvals as first or second line indications since 2015. These include immune checkpoint blocking antibodies, chimeric antigen receptor-transduced T-cells and bispecific T-cell-engaging antibodies. While multiple cancer types now benefit from these immunotherapies, notable exceptions thus far include brain tumors, such as glioblastoma. As such, it seems critical to gain a better understanding of unique mechanistic challenges underlying the resistance of malignant gliomas to immunotherapy, as well as to acquire insights in the development of future strategies. An Immuno-Oncology Think Tank Meeting was held during the 2019 Annual Society for Neuro-Oncology Scientific Conference. Discussants in the fields of neuro-oncology, neurosurgery, neuro-imaging, medical oncology, and cancer immunology participated in the meeting. Sessions focused on topics such as the tumor microenvironment, myeloid cells and T-cell dysfunction, cellular engineering, and translational aspects that are critical and unique challenges inherent with primary brain tumors. In this review, we summarize the discussions and the key messages from the meeting, which may potentially serve as a basis for advancing the field of immune neuro-oncology in a collaborative manner.
View details for DOI 10.1093/neuonc/noaa277
View details for PubMedID 33367885